Analysts expect that American Renal Associates Holdings Inc (NYSE:ARA) will post sales of $217.42 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for American Renal Associates’ earnings, with the lowest sales estimate coming in at $217.24 million and the highest estimate coming in at $217.60 million. The business is scheduled to report its next earnings report on Tuesday, February 4th.
On average, analysts expect that American Renal Associates will report full year sales of $833.84 million for the current year, with estimates ranging from $833.68 million to $834.00 million. For the next financial year, analysts forecast that the firm will post sales of $876.69 million, with estimates ranging from $875.37 million to $878.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow American Renal Associates.
American Renal Associates (NYSE:ARA) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.33 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.37. The firm had revenue of $211.43 million for the quarter, compared to analyst estimates of $215.06 million. American Renal Associates had a negative net margin of 1.75% and a positive return on equity of 23.16%.
Shares of ARA traded up $0.22 during midday trading on Monday, reaching $9.65. The stock had a trading volume of 267,637 shares, compared to its average volume of 209,893. The firm has a 50 day simple moving average of $8.67 and a 200-day simple moving average of $7.43. American Renal Associates has a one year low of $5.48 and a one year high of $16.62. The company has a debt-to-equity ratio of 8.05, a quick ratio of 0.97 and a current ratio of 1.01.
A number of institutional investors and hedge funds have recently bought and sold shares of ARA. Morgan Stanley lifted its holdings in American Renal Associates by 68.5% during the 2nd quarter. Morgan Stanley now owns 5,932 shares of the company’s stock valued at $44,000 after purchasing an additional 2,412 shares during the last quarter. Panagora Asset Management Inc. acquired a new position in shares of American Renal Associates in the second quarter valued at $47,000. Tower Research Capital LLC TRC increased its holdings in shares of American Renal Associates by 347.3% in the third quarter. Tower Research Capital LLC TRC now owns 8,705 shares of the company’s stock valued at $55,000 after purchasing an additional 6,759 shares during the last quarter. Stone Ridge Asset Management LLC acquired a new position in shares of American Renal Associates in the second quarter valued at $98,000. Finally, Parametric Portfolio Associates LLC bought a new position in shares of American Renal Associates in the second quarter valued at about $114,000. Institutional investors and hedge funds own 85.40% of the company’s stock.
American Renal Associates Company Profile
American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.
Further Reading: What is the S&P/TSX Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.